Alliqua Biomedical (NASDAQ:ALQA) was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating in a report released on Thursday.
Separately, HC Wainwright lowered Alliqua Biomedical from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $4.50 to $2.80 in a report on Monday, January 8th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Alliqua Biomedical currently has a consensus rating of “Hold” and an average price target of $8.20.
Shares of Alliqua Biomedical (NASDAQ:ALQA) traded up $0.02 during midday trading on Thursday, reaching $1.68. The company’s stock had a trading volume of 16,681 shares, compared to its average volume of 95,560. Alliqua Biomedical has a 52-week low of $1.58 and a 52-week high of $8.48. The firm has a market cap of $8.33, a price-to-earnings ratio of -0.17 and a beta of 1.68.
About Alliqua Biomedical
Alliqua BioMedical, Inc is a provider of advanced wound care solutions. The Company’s businesses include advanced wound care and contract manufacturing. The Company operates through its subsidiaries, such as AquaMed Technologies, Inc and Choice Therapeutics, Inc The Company is engaged in developing a suite of advanced wound care solutions that will enable surgeons, clinicians and wound care practitioners to address the challenges in chronic and acute wounds.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Alliqua Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliqua Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.